Human alpha-folate receptor chimeric antigen receptor
AssigneesThe Trustees of the University of Pennsylvania, Fondazione Irccs Istituto Nazionale Dei Tumori
InventorsDaniel J. Powell, JR., Mariangela Figini, Silvana Canevari
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.
Claims26
1-29. (canceled)
A method for treating cancer in a subject, the method comprising:
- administering an effective amount of a genetically modified T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) to the subject, wherein the CAR comprises an α-folate receptor (FRα) binding domain, an intracellular domain of a costimulatory molecule, a transmembrane domain, and a CD3 zeta signaling domain, thereby treating the cancer in the subject.
A method for stimulating a T cell-mediated immune response to a cell population or tissue in a subject, the method comprising:
- administering an effective amount of a genetically modified T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) to the subject, wherein the CAR comprises an α-folate receptor (FRα) binding domain, an intracellular domain of a costimulatory molecule, a transmembrane domain, and a CD3 zeta signaling domain, thereby stimulating a T cell-mediated immune response to the cell population or tissue in the subject.
A method for generating a persisting population of genetically engineered T cells in a subject diagnosed with cancer, the method comprising:
- administering an effective amount of a genetically modified T cell comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR) to the subject, wherein the CAR comprises an α-folate receptor (FRα) binding domain, an intracellular domain of a costimulatory molecule, a transmembrane domain, and a CD3 zeta signaling domain, wherein the persisting population of genetically engineered T cells persists in the subject for at least one month after administration.
Dependencies are inferred from the claim text.